Moreover, a high co-expression of REEP6/CD166 (AHR = 2.28, 95%CI = 1.10–4.75, p = 0.027, Table 4), REEP6/ABCG2 (AHR = 3.65, 95%CI = 1.42–9.41, p = 0.007, Table 4) and REEP6/ALDH1A1 (AHR = 3.25, 95%CI = 1.34–7.90, p = 0.009, Table 4) was related to the DFS of oral cancer patients in the TCGA database. Here, REEP6 is linked to lip and oral cavity carcinoma.